Shedding light on serum vitamin D concentrations and the risk of rarer cancers

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 1, 2013, Pages 65-69

  Helzlsouer, Kathy J ^a,b   Gallicchio, Lisa ^a,b,c  

^a Mercy Medical Center   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

25 hydroxyvitamin D; Bladder cancer; Cancer; Cohort; Endometrial cancer; Esophageal cancer; Gastric cancer; Kidney cancer; Nested case control study; Non hodgkin lymphoma; Ovarian cancer; Pancreatic cancer; Prospective studies; Vitamin D

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; VITAMIN D;

CANCER RISK; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; HAZARD RATIO; HUMAN; KIDNEY CANCER; NEOPLASM; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; REVIEW; STOMACH CANCER;

EID: 84879022948     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152013804487326     Document Type: Review

References (28)

1. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. 2011. Washington DC, National Academies Press.
2. Byers, T. Anticancer vitamins du Jour--The ABCED's so far. Am. J. Epidemiol., 2010, 172(1), 1-3.
3. Albanes, D.; Heinonen, O.P.; Huttunen, J.K.; Taylor, P.R.; Virtamo, J.; Edwards, B.K.; Haapakoski, J.; Rautalahti, M.; Hartman, A.M.; Palmgren, J. Effects of alpha-tocopherol and betacarotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am. J.Clin. Nutr., 1995, 62(6 Suppl):1427S-1430S.
4. Omenn, G.S.; Goodman, G.E.; Thornquist, M.D.; Balmes, J.; Cullen, M.R.; Glass, A.; Keogh, J.P.; Meyskens, F.L.; Valanis, B.; Williams, J.H.; Barnhart, S.; Hammar, S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med., 1996, 334(18), 1150-1155.
5. Cole, B.F.; Baron, J.A.; Sandler, R.S.; Haile, R.W.; Ahnen, D.J.; Bresalier, R.S.; Keown-Eyssen, G.; Summers, R.W.; Rothstein, R.I.; Burke, C.A.; Snover, D.C.; Church, T.R.; Allen, J.I.; Robertson, D.J.; Beck, G.J.; Bond, J.H.; Byers, T.; Mandel, J.S.; Mott, L.A.; Pearson, L.H.; Barry, E.L.; Rees, J.R.; Marcon, N.; Saibil, F.; Ueland, P.M.; Greenberg, E.R. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA, 2007, 297(21), 2351-2359.
6. Klein, E.A.; Thompson, I.M. Jr.; Tangen, C.M.; Crowley, J.J.; Lucia, M.S.; Goodman, P.J.; Minasian, L.M.; Ford, L.G.; Parnes, H.L.; Gaziano, J.M.; Karp, D.D.; Lieber, M.M.; Walther, P.J.; Klotz, L.; Parsons, J.K.; Chin, J.L.; Darke AK, Lippman SM, Goodman GE, Meyskens FL, Jr., Baker, L.H. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 2011, 306(14), 1549-1556.
7. Helzlsouer, K.J. Overview of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am. J. Epidemiol., 2010, 172(1), 4-9.
8. Nutrition Business Journal. A response to Consumer Reports' scary supplements. Nutrition Business Journal 2010 August 3 [cited 2012 Aug 3];Available from: URL: http://newhope360.com/herbsmedicinals/ response-consumer-reports-scary-supplements
9. Manson, J.E.; Bassuk, S.S.; Lee, I.M.; Cook, N.R.; Albert, M.A.; Gordon, D.; Zaharris, E.; Macfadyen, J.G.; Danielson, E.; Lin, J.; Zhang, S.M.; Buring, J.E. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp. Clin. Trial., 2012, 33(1):159-171.
10. Stolzenberg-Solomon, R.Z.; Vieth, R.; Azad, A.; Pietinen, P.; Taylor, P.R.; Virtamo, J.; Albanes, D. A prospective nested casecontrol study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res., 2006, 66(20), 10213-10219.
11. Stolzenberg-Solomon, R.Z.; Hayes, R.B.; Horst, R.L.; Anderson, K.E.; Hollis, B.W.; Silverman, D.T. Serum vitamin D and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian screening trial. Cancer Res., 2009, 69(4), 1439-1447.
12. Stolzenberg-Solomon, R.Z.; Jacobs, E.J.; Arslan, A.A.; Qi, D.; Patel, A.V.; Helzlsouer, K.J.; Weinstein, S.J.; McCullough, M.L.; Purdue, M.P.; Shu, X.O.; Snyder, K.; Virtamo, J.; Wilkins, L.R.; Yu, K.; Zeleniuch-Jacquotte, A.; Zheng, W.; Albanes, D.; Cai, Q.; Harvey, C.; Hayes, R.; Clipp, S.; Horst, R.L.; Irish, L.; Koenig, K., Le, M.L.; Kolonel, L.N. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am. J. Epidemiol., 2010, 172(1), 81-93.
13. Wolpin, B.M.; Ng, K.; Bao, Y.; Kraft, P.; Stampfer, M.J.; Michaud, D.S.; Ma, J.; Buring, J.E.; Sesso, H.D.; Lee, I.M.; Rifai, N. Cochrane, B.B.; Wactawski-Wende, J.; Chlebowski, R.T.; Willett, W.C.; Manson, J.E.; Giovannucci, E.L.; Fuchs, C.S. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol. Biomarkers Prev., 2012, 21(1), 82-91.
14. Weinstein, S.J.; Stolzenberg-Solomon, R.Z.; Kopp, W.; Rager, H.; Virtamo, J.; Albanes, D. Impact of Circulating Vitamin D Binding Protein Levels on the Association between 25-Hydroxyvitamin D and Pancreatic Cancer Risk: A Nested Case-Control Study. Cancer Res., 2012, 72(5), 1190-1198.
15. Lim, U.; Freedman, D.M.; Hollis, B.W.; Horst, R.L.; Purdue, M.P.; Chatterjee, N.; Weinstein, S.J.; Morton, L.M.; Schatzkin, A.; Virtamo, J.; Linet, M.S.; Hartge, P.; Albanes, D. A prospective investigation of serum 25-hydroxyvitamin D and risk of lymphoid cancers. Int. J. Cancer, 2009, 124(4), 979-986.
16. Purdue, M.P.; Freedman, D.M.; Gapstur, S.M.; Helzlsouer, K.J.; Laden, F.; Lim, U.; Maskarinec, G.; Rothman, N.; Shu, X.O.; Stevens, V.L.; Zeleniuch-Jacquotte, A.; Albanes, D.; Bertrand, K.; Weinstein, S.J.; Yu, K.; Irish, L.; Horst, R.L.; Hoffman-Bolton, J.; Giovannucci, E.L.; Kolonel, L.N.; Snyder, K.; Willett, W.; Arslan, A.A.; Hayes, R.B.; Zheng, W.; Xiang, Y.B.; Hartge, P. Circulating 25-hydroxyvitamin D and risk of nonhodgkin lymphoma: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am. J. Epidemiol., 2010, 172(1), 58-69.
17. Bertrand, K.A.; Chang, E.T.; Abel, G.A.; Zhang, S.M.; Spiegelman, D.; Qureshi, A.A.; Laden, F. Sunlight exposure, vitamin D, and risk of non-Hodgkin lymphoma in the Nurses' Health Study. Cancer Causes Control, 2011, 22(12), 1731-1741.
18. Tworoger, S.S.; Lee, I.M.; Buring, J.E.; Rosner, B.; Hollis, B.W.; Hankinson, S.E. Plasma 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D and risk of incident ovarian cancer. Cancer Epidemiol. Biomarkers Prev., 2007, 16(4), 783-788.
19. Arslan, A.A.; Clendenen, T.V.; Koenig, K.L.; Hultdin, J.; Enquist, K.; Agren, A.; Lukanova, A.; Sjodin, H.; Zeleniuch-Jacquotte, A.; Shore, R.E.; Hallmans, G.; Toniolo, P.; Lundin, E. Circulating vitamin d and risk of epithelial ovarian cancer. J. Oncol., 2009, 2009, 672492.
20. Toriola, A.T.; Surcel, H.M.; Agborsangaya, C.; Grankvist, K.; Tuohimaa, P.; Toniolo, P.; Lukanova, A.; Pukkala, E.; Lehtinen, M. Serum 25-hydroxyvitamin D and the risk of ovarian cancer. Eur. J. Cancer, 2010, 46(2), 364-369.
21. Zheng, W.; Danforth, K.N.; Tworoger, S.S.; Goodman, M.T.; Arslan, A.A.; Patel, A.V.; McCullough, M.L.; Weinstein, S.J.; Kolonel, L.N.; Purdue, M.P.; Shu, X.O.; Snyder, K.; Steplowski, E.; Visvanathan, K.; Yu, K.; Zeleniuch-Jacquotte, A.; Gao, Y.T.; Hankinson, S.E.; Harvey, C.; Hayes, R.B.; Henderson, B.E.; Horst, R.L.; Helzlsouer, K.J. Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am. J. Epidemiol., 2010, 172(1), 70-80.
22. Zeleniuch-Jacquotte, A.; Gallicchio, L.; Hartmuller, V.; Helzlsouer, K.J.; McCullough, M.L.; Setiawan, V.W.; Shu, X.O.; Weinstein, S.J.; Weiss, J.M.; Arslan, A.A.; De, V. I.; Gao, Y.T.; Hayes, R.B.; Henderson, B.E.; Horst, R.L.; Koenig, K.L.; Patel, A.V.; Purdue, M.P.; Snyder, K.; Steplowski, E.; Yu, K.; Zheng, W.; Hankinson, S.E. Circulating 25-hydroxyvitamin D and risk of endometrial cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am. J. Epidemiol., 2010, 172(1), 36-46.
23. Gallicchio, L.; Moore, L.E.; Stevens, V.L.; Ahn, J.; Albanes, D.; Hartmuller, V.; Setiawan, V.W.; Helzlsouer, KJ, Yang G, Xiang YB, Shu XO, Snyder K, Weinstein SJ, Yu K, Zeleniuch-Jacquotte A, Zheng W, Cai Q, Campbell DS, Chen Y, Chow WH, Horst RL, Kolonel LN, McCullough ML, Purdue MP, Koenig KL. Circulating 25-hydroxyvitamin D and risk of kidney cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am. J. Epidemiol., 2010, 172(1), 47-57.
24. Mondul AM, Weinstein SJ, Mannisto S, Snyder K, Horst RL, Virtamo J, Albanes D. Serum vitamin D and risk of bladder cancer. Cancer Res., 2010, 70(22), 9218-9223.
25. Chen W, Dawsey SM, Qiao YL, Mark SD, Dong ZW, Taylor PR, Zhao P, Abnet CC. Prospective study of serum 25(OH)-vitamin D concentration and risk of oesophageal and gastric cancers. Br. J. Cancer, 2007, 97(1), 123-128.
26. Abnet CC, Chen Y, Chow WH, Gao YT, Helzlsouer KJ, Le ML, McCullough ML, Shikany JM, Virtamo J, Weinstein SJ, Xiang YB, Yu K, Zheng W, Albanes D, Arslan AA, Campbell DS, Campbell PT, Hayes RB, Horst RL, Kolonel LN, Nomura AM, Purdue MP, Snyder K, Shu XO. Circulating 25-hydroxyvitamin D and risk of esophageal and gastric cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am. J. Epidemiol., 2010, 172(1), 94-106.
27. Jorde R, Sneve M, Hutchinson M, Emaus N, Figenschau Y, Grimnes G. Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. Am. J. Epidemiol., 2010, 171(8): 903-908.
28. Brunner RL, Wactawski-Wende J, Caan BJ, Cochrane BB, Chlebowski RT, Gass ML, Jacobs ET, LaCroix AZ, Lane D, Larson J, Margolis KL, Millen AE, Sarto GE, Vitolins MZ, Wallace RB. The effect of calcium plus vitamin D on risk for invasive cancer: results of the Women's Health Initiative (WHI) calcium plus vitamin D randomized clinical trial. Nutr. Cancer, 2011, 63(6), 827-841.